Home The pathway through LC-MS method development: in-house or ready-to-use kit-based methods?
Article
Licensed
Unlicensed Requires Authentication

The pathway through LC-MS method development: in-house or ready-to-use kit-based methods?

  • Caroline Le Goff EMAIL logo , Jordi Farre-Segura , Violeta Stojkovic , Patrice Dufour , Stéphanie Peeters , Justine Courtois , Adrien Nizet , Nathalie De Vos and Etienne Cavalier
Published/Copyright: February 18, 2020
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 58 Issue 6

Abstract

Historically, the determination of low concentration analytes was initially made possible by the development of rapid and easy-to-perform immunoassays (IAs). Unfortunately, typical problems inherent to IA technologies rapidly appeared (e.g. elevated cost, cross-reactivity, lot-to-lot variability, etc.). In turn, liquid chromatography tandem mass spectrometry (LC-MS/MS) methods are sensitive and specific enough for such analyses. Therefore, they would seem to be the most promising candidates to replace IAs. There are two main choices when implementing a new LC-MS/MS method in a clinical laboratory: (1) Developing an in-house method or (2) purchasing ready-to-use kits. In this paper, we discuss some of the respective advantages, disadvantages and mandatory requirements of each choice. Additionally, we also share our experiences when developing an in-house method for cortisol determination and the implementation of an “ready-to-use” (RTU) kit for steroids analysis.

Keywords: in-house method; kit ready to use; mass spectrometry

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Vogeser M, Seger C. LC–MS/MS in clinical chemistry. J Chromatogr B 2012;883–884:1–2.10.1016/j.jchromb.2012.01.001Search in Google Scholar PubMed

2. Carvalho VM. The coming of age of liquid chromatography coupled to tandem mass spectrometry in the endocrinology laboratory. J Chromatogr B Anal Technol Biomed Life Sci 2012;883–884:50–8.10.1016/j.jchromb.2011.08.027Search in Google Scholar PubMed

3. Hunter WM, Budd PS. Circulating antibodies to ovine and bovine immunoglobin in healthy subjects: a hazard for immunoassays. Lancet 1980;316:1136.10.1016/S0140-6736(80)92565-9Search in Google Scholar

4. Al-Dujaili EA, Edwards CR. Development and application of a simple radioimmunoassay for urinary aldosterone. Clin Chim Acta 1981;116:277–87.10.1016/0009-8981(81)90047-4Search in Google Scholar PubMed

5. Cavalier E, Lukas P, Bekaert A-C, Peeters S, Le Goff C, Yayo E, et al. Analytical and clinical evaluation of the new Fujirebio Lumipulse® G non-competitive assay for 25(OH)-Vitamin D and three immunoassays for 25(OH)D in healthy subjects, osteoporotic patients, third trimester pregnant women, healthy African subjects, hemodialyzed and intensive care patients. Clin Chem Lab Med 2016;54:1347–55.10.1515/cclm-2015-0923Search in Google Scholar PubMed

6. Cavalier E, Rousselle O, Ferrante N, Carlisi A, Le Goff C, Souberbielle J-C. Technical and clinical evaluation of the VITROS® immunodiagnostic products 25-OH vitamin D total assay – comparison with marketed automated immunoassays and a liquid chromatography tandem mass spectrometry method. Clin Chem Lab Med 2013;51:1983–9.10.1515/cclm-2013-0138Search in Google Scholar PubMed

7. Dorrian CA, Toole BJ, Alvarez-Madrazo S, Kelly A, Connell JM, Wallace AM. A screening procedure for primary aldosteronism based on the Diasorin Laision automated chemilumuniscent immunoassay for direct renin. Ann Clin Biochem 2010;47:195–9.10.1258/acb.2010.009230Search in Google Scholar PubMed

8. Horton R, Hawks D, Lobo R. 3a, 17f-androstanediol glucuronide in plasma. A marker of androgen action in idiopathic hirsutism. J Clin Invest 1982;69:1203–6.10.1172/JCI110558Search in Google Scholar

9. Wu AH, French D. Implementation of liquid chromatography/mass spectrometry into the clinical laboratory. Clin Chim Acta 2013;420:4–10.10.1016/j.cca.2012.10.026Search in Google Scholar PubMed

10. Meunier C, Blondelle D, Faure P, Baguet J-P, Le Goff C, Chabre O, et al. Development and validation of a method using supported liquid extraction for aldosterone determination in human plasma by LC-MS/MS. Clin Chim Acta 2015;447:8–15.10.1016/j.cca.2015.05.007Search in Google Scholar PubMed

11. Le Goff CM, Gonzalez-Antuña A, Peeters SD, Fabregat-Cabello N, Van Der Gugten JG, Vroonen L, et al. Migration from RIA to LC-MS/MS for aldosterone determination: Implications for clinical practice and determination of plasma and urine reference range intervals in a cohort of healthy Belgian subjects. Clin Mass Spectrom 2018;9:7–17.10.1016/j.clinms.2018.06.002Search in Google Scholar

12. Perich C, Minchinela J, Ricós C, Fernández-Calle P, Alvarez V, Doménech MV, et al. Biological variation database: structure and criteria used for generation and update. Clin Chem Lab Med 2015;53:299–305.10.1515/cclm-2014-0739Search in Google Scholar PubMed

13. Fraser CG, Petersen PH. Analytical performance characteristics should be judged against objective quality specifications. Clin Chem 1999;45:321–3.10.1093/clinchem/45.3.321Search in Google Scholar

14. Kushnir MM, Rockwood AL, Bergquist J, Varshavsky M, Roberts WL, Yue B, et al. High-sensitivity tandem mass spectrometry assay for serum estrone and estradiol. Am J Clin Pathol 2008;129:530–9.10.1309/LC03BHQ5XJPJYEKGSearch in Google Scholar PubMed

15. Shiraishi S, Lee PW, Leung A, Goh VH, Swerdloff RS, Wang C. Simultaneous measurement of serum testosterone and dihydrotestosterone by liquid chromatography-tandem mass spectrometry. Clin Chem 2008;54:1855–63.10.1373/clinchem.2008.103846Search in Google Scholar PubMed

16. Lynch KL. CLSI C62-A: A new standard for clinical mass spectrometry. Clin Chem 2016;62:24–9.10.1373/clinchem.2015.238626Search in Google Scholar PubMed

17. Van den Ouweland JM, Kema IP. The role of liquid chromatography-tandem mass spectrometry in the clinical laboratory. J Chromatogr B Anal Technol Biomed Life Sci 2012;883–884:18–32.10.1016/j.jchromb.2011.11.044Search in Google Scholar PubMed

18. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 2003;75:3019–30.10.1021/ac020361sSearch in Google Scholar PubMed

19. Keevil BG. LC–MS/MS analysis of steroids in the clinical laboratory. Clin Biochem 2016;49:989–97.10.1016/j.clinbiochem.2016.04.009Search in Google Scholar PubMed

20. Vogeser M. Pitfalls associated with the use of liquid chromatography-tandem mass spectrometry in the clinical laboratory. Clin Chem 2008;54:1406–8.10.1373/clinchem.2009.138602Search in Google Scholar PubMed

21. Carvalho VM, Nakamura OH, Vieira JG. Simultaneous quantitation of seven endogenous C-21 adrenal steroids by liquid chromatography tandem mass spectrometry in human serum. J Chromatogr B Anal Technol Biomed Life Sci 2008;872:154–61.10.1016/j.jchromb.2008.07.035Search in Google Scholar PubMed

22. Solberg HE. The IFCC recommendation on estimation of reference intervals. The RefVal program. Clin Chem Lab Med 2004;42:710–4.10.1515/CCLM.2004.121Search in Google Scholar PubMed

Supplementary Material

The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2019-0916).

Received: 2019-08-29
Accepted: 2020-01-21
Published Online: 2020-02-18
Published in Print: 2020-06-25

©2020 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Advancements in mass spectrometry as a tool for clinical analysis: part II
  4. Quantitative protein assessment
  5. Complexity, cost, and content – three important factors for translation of clinical protein mass spectrometry tests, and the case for apolipoprotein C-III proteoform testing
  6. Vedolizumab quantitation using high-resolution accurate mass-mass spectrometry middle-up protein subunit: method validation
  7. Development and evaluation of an element-tagged immunoassay coupled with inductively coupled plasma mass spectrometry detection: can we apply the new assay in the clinical laboratory?
  8. MALDI-MS for the clinic
  9. Matrix-assisted laser desorption ionisation (MALDI) mass spectrometry (MS): basics and clinical applications
  10. Clinical use of mass spectrometry (imaging) for hard tissue analysis in abnormal fracture healing
  11. Cellular resolution in clinical MALDI mass spectrometry imaging: the latest advancements and current challenges
  12. Bacterial identification by lipid profiling using liquid atmospheric pressure matrix-assisted laser desorption/ionization mass spectrometry
  13. Clinical application of ’omics technologies
  14. Individualized metabolomics: opportunities and challenges
  15. Diagnostic amyloid proteomics: experience of the UK National Amyloidosis Centre
  16. The “olfactory fingerprint”: can diagnostics be improved by combining canine and digital noses?
  17. Peptidomic and proteomic analysis of stool for diagnosing IBD and deciphering disease pathogenesis
  18. The influence of hypoxia on the prostate cancer proteome
  19. Laboratory automation and kit-based approaches
  20. Mass spectrometry and total laboratory automation: opportunities and drawbacks
  21. The pathway through LC-MS method development: in-house or ready-to-use kit-based methods?
  22. Evaluation of the 25-hydroxy vitamin D assay on a fully automated liquid chromatography mass spectrometry system, the Thermo Scientific Cascadion SM Clinical Analyzer with the Cascadion 25-hydroxy vitamin D assay in a routine clinical laboratory
https://doi.org/10.1515/cclm-2019-0916
Keywords for this article
in-house method; kit ready to use; mass spectrometry

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Advancements in mass spectrometry as a tool for clinical analysis: part II
  4. Quantitative protein assessment
  5. Complexity, cost, and content – three important factors for translation of clinical protein mass spectrometry tests, and the case for apolipoprotein C-III proteoform testing
  6. Vedolizumab quantitation using high-resolution accurate mass-mass spectrometry middle-up protein subunit: method validation
  7. Development and evaluation of an element-tagged immunoassay coupled with inductively coupled plasma mass spectrometry detection: can we apply the new assay in the clinical laboratory?
  8. MALDI-MS for the clinic
  9. Matrix-assisted laser desorption ionisation (MALDI) mass spectrometry (MS): basics and clinical applications
  10. Clinical use of mass spectrometry (imaging) for hard tissue analysis in abnormal fracture healing
  11. Cellular resolution in clinical MALDI mass spectrometry imaging: the latest advancements and current challenges
  12. Bacterial identification by lipid profiling using liquid atmospheric pressure matrix-assisted laser desorption/ionization mass spectrometry
  13. Clinical application of ’omics technologies
  14. Individualized metabolomics: opportunities and challenges
  15. Diagnostic amyloid proteomics: experience of the UK National Amyloidosis Centre
  16. The “olfactory fingerprint”: can diagnostics be improved by combining canine and digital noses?
  17. Peptidomic and proteomic analysis of stool for diagnosing IBD and deciphering disease pathogenesis
  18. The influence of hypoxia on the prostate cancer proteome
  19. Laboratory automation and kit-based approaches
  20. Mass spectrometry and total laboratory automation: opportunities and drawbacks
  21. The pathway through LC-MS method development: in-house or ready-to-use kit-based methods?
  22. Evaluation of the 25-hydroxy vitamin D assay on a fully automated liquid chromatography mass spectrometry system, the Thermo Scientific Cascadion SM Clinical Analyzer with the Cascadion 25-hydroxy vitamin D assay in a routine clinical laboratory
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 23.11.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2019-0916/html
Scroll to top button